Checked.be
Active
BE 0471.881.541Private limited company
NAID
Acaciaslaan(D) 28 ·7711 Mouscron, Belgium· 26 yrs active
Sector: Specialist medical practice
(86220)
Conclusion
NAID has been active since 2000 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €678k and a net result of €240k. Equity is growing by ~35.7% per year across the filed fiscal years. Its solvency ranks better than 41% of 16012 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is < 0.1% (very low).
Based on the State Gazette, CBE and 5 annual accounts.
Key figures
| Equity | €678k |
| Net result | €240k |
| Staff (FTE) | 2.1 |
| Better than sector | 41% |
Financial profile
89
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
88
Profitability
100
Solvency
78
Growth
78
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Long-established
Founded in 2000, 26 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
88
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€60k
estimate, not credit advice
Score history
43
2021
36
2022
51
2023
71
2024
88
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 1.11 (≥ 1.0)
+5
Quick ratio
Quick ratio 1.11 (≥ 1.0)
+5
Leverage
Debt/equity 0.75 (< 1.0)
+10
Profitability
ROE 35% (≥ 10%)
+10
Interest coverage
Interest coverage 3.7× (≥ 3×)
+8
Profit trend
Net profit down YoY
-3
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 10-07-2026 with the NBB · fiscal year 2025 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~35.7%/year over 5 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 52.9% | 63.4% | |
| Net result | €240k | €62k | |
| Equity | €678k | €132k | |
| Gross operating margin | €587k | €116k | |
| Staff costs | €43k | €29k |
€519k
-3.1%
21-25
€240k
-14.7%
21-25
€271k
-10.7%
21-25
€1.28M
+2.7%
21-25
€678k
+13.5%
21-25
€45k
-
21-25
2
+23.5%
21-25
€43k
+10.6%
21-25
€108k
-15.4%
21-25
€159k
+184.1%
21-25
€507k
-9.1%
21-25
€415k
+15.0%
21-25
€92k
-53.3%
21-25
1.11
+140.6%
21-25
1.11
+140.6%
21-25
52.9%
+10.5%
21-25
0.75
-19.9%
21-25
35.4%
-24.9%
21-25
18.7%
-17.0%
21-25
3.70
-27.6%
21-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - | - |
| EBITDA | €519k | €535k | €388k | €342k | €337k |
| Net profit | €240k | €282k | €116k | €20k | €92k |
| Cash flow | €271k | €303k | €212k | €230k | €150k |
| Staff costs | €43k | €39k | €24k | - | - |
| Income taxes | €108k | €128k | €50k | €9k | €39k |
| Dividends | €159k | €56k | - | €0 | €70k |
| Total assets | €1.28M | €1.25M | €1.63M | €1.76M | €1.39M |
| Equity | €678k | €598k | €372k | €256k | €236k |
| Debt | €507k | €558k | €1.17M | €1.42M | €1.07M |
| of which ≤ 1y | €415k | €361k | €810k | €1.07M | €969k |
| of which > 1y | €92k | €197k | €362k | €356k | €102k |
| Working capital | €45k | €-195k | €-683k | €-606k | €-235k |
| Employees (FTE) | 2.1 | 1.7 | - | - | - |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 1.11 | 0.46 | 0.16 | 0.43 | 0.76 |
| Quick ratio | 1.11 | 0.46 | 0.16 | 0.43 | 0.76 |
| Working capital ratio | 3.5% | -15.6% | -41.8% | -34.4% | -17.0% |
| Solvency | 52.9% | 47.9% | 22.8% | 14.6% | 17.0% |
| Debt / equity | 0.75 | 0.93 | 3.15 | 5.56 | 4.55 |
| Long-term debt ratio | 0.14 | 0.33 | 0.97 | 1.39 | 0.43 |
| Interest coverage | 3.70 | 5.11 | 3.04 | 3.32 | 2.28 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | 18.7% | 22.6% | 7.1% | 1.1% | 6.6% |
| ROE | 35.4% | 47.1% | 31.1% | 7.9% | 39.1% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (26 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €1.28M | €1.25M | €1.63M | €1.76M | €1.39M |
| Fixed assets | 21/28 | €821k | €1.08M | €1.50M | €1.30M | €654k |
| Tangible fixed assets | 22/27 | €821k | €1.08M | €1.50M | €1.30M | €653k |
| Financial fixed assets | 28 | €950 | €950 | €1k | €1k | €1k |
| Current assets | 29/58 | €460k | €166k | €127k | €462k | €733k |
| Amounts receivable within one year | 40/41 | €25k | €30k | €45k | €73k | €64k |
| Investments | 50/53 | €410k | €10k | €10k | €10k | €10k |
| Cash & bank | 54/58 | €23k | €126k | €72k | €374k | €655k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.28M | €1.25M | €1.63M | €1.76M | €1.39M |
| Equity | 10/15 | €678k | €598k | €372k | €256k | €236k |
| Contributions / capital | 10/11 | €41k | €41k | €41k | €41k | €41k |
| Reserves | 13 | €643k | €562k | €337k | €221k | €201k |
| Accumulated profits (losses) | 14 | €-6k | €-6k | €-6k | €-6k | €-6k |
| Provisions & deferred taxes | 16 | €96k | €92k | €88k | €80k | €79k |
| Amounts payable | 17/49 | €507k | €558k | €1.17M | €1.42M | €1.07M |
| Amounts payable after one year | 17 | €92k | €197k | €362k | €356k | €102k |
| Amounts payable within one year | 42/48 | €415k | €361k | €810k | €1.07M | €969k |
| Trade debts payable within one year | 44 | €2k | €9k | €15k | €41k | €2k |
| Income statement | ||||||
| Gross operating margin | 9900 | €587k | €587k | €432k | €351k | €281k |
| Operating result | 9901 | €488k | €514k | €292k | €132k | €280k |
| Financial income | 75 | €202 | €255 | €1k | €123 | €88 |
| Financial charges | 65 | €140k | €105k | €127k | €103k | €148k |
| Result before taxes | 9903 | €348k | €409k | €166k | €29k | €132k |
| Income taxes | 67/77 | €108k | €128k | €50k | €9k | €39k |
| Net result for the period | 9904 | €240k | €282k | €116k | €20k | €92k |
| Result to be appropriated | 9905 | €240k | €282k | €116k | €20k | €92k |
Legal Structure
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 15-05-2000 |
| Status | Active |
| Postal code | 7711 |
Establishment units
NAID
since 20002.341.477.456
Real-estate footprint
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 54006N0446/00_000 | Wallonia | 1,633 m² | 1 · 254 m² | 7.8 m · 2 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
10-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Liquidity doublescurrent ratio 1.11
Current ratio from 0.46 to 1.11.
01-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Highest result since 2021net €282k ▲143%
Operating result €514k, net result €282k, both a record.
31-12
Financial
Equity above €500kEq €598k ▲60.6%
4 profitable years in a row build equity to €598k.
21-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 21 days late
2023
14-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Weakest financial yearnet €20k ▼78.2%
Net result drops to €20k, the lowest in the series; recovery starts the following year.
26-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
29-06
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
16-06
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
09-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 9 days late
2018
28-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 28 days late
2017
31-07
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Specialist medical practice86220
Names & trade names
| Legal nameFR | NAID |
Similar companies
DOKTER DAVID VANWYNSBERGHE, OPHTALMOLOOG
BE 0832.144.390 · Gent
Dokter SCHUMMER
BE 0444.538.825 · Diest
Dermatoloog Raes
BE 0848.730.105 · Hoogstraten
DR. DE CUYPER EVA
BE 0822.147.452 · Genk
ENDOCRINE UNIT
BE 0478.931.263 · Oudergem